SafetyMargin.ioSafetyMargin.io
BlogWatchlistCompare
Compare Stocks › REGN vs V

Regeneron Pharmaceuticals, Inc. (REGN) vs Visa Inc. (V): Which Is the Better Buy in 2026?

As of 2026-06-19, REGN is undervalued at $610, with a DCF intrinsic value of $1572 and a margin of safety of 61%. V is fairly valued at $327, with an intrinsic value of $304 and a margin of safety of -8%. Of the two, REGN has the wider margin of safety.

REGN
Regeneron Pharmaceuticals, Inc.
$609.94
VS
V
Visa Inc.
$327.24

Rewards

REGN
  • ★Regeneron Pharmaceuticals, Inc. scores 80/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • ★Trailing P/E of 14.9x is 22% below the historical average of 19.2x — potentially undervalued relative to its own history.
  • ★Altman Z-Score of 7.56 indicates very low bankruptcy risk — the company is firmly in the safe zone.
V
  • ★Visa Inc. has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • ★Gross margin of 97.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • ★Visa Inc. scores 99/100 on the Economic Moat Score (Wide Moat), with roic consistency as the strongest competitive dimension.

Risks

REGN
  • ⚠ROIC has declined by 7.3 percentage points over the past 4 years, which may signal competitive erosion.
  • ⚠Each dollar of retained earnings has produced only $0.15 of earning power — shareholders may have been better served by dividends.
  • ⚠FCF yield of 5.1% suggests reasonable valuation assuming continued moderate growth.
V
  • ⚠Insiders have sold $14.2M worth of stock in the past 3 months — significant insider liquidation.

Key Valuation Metrics

Learn more →
REGN
V
Valuation
$3.27B
Free Cash Flow
$20.84B
5.12%
FCF Yield
3.35%
14.90
Trailing P/E
28.55
11.34
Forward P/E
22.02
Quality & Moat
7.13%
ROIC
38.39%
14.55%
ROE
60.35%
43.89%
Gross Margin
97.78%
1.07
PEG Ratio
1.46
Balance Sheet Safety
Net cash
Net Debt / Equity
0.28
N/A
Interest Coverage
N/A
-1.38
Net Debt / EBITDA
0.33
0.61%
Dividend Yield
0.80%
REGN: 6Ties: 1V: 5
REGNV

Historical Fundamentals

Learn more →
REGN

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

V

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
REGN
$0.20
created per $1 retained over 3 years
Value Destroyer
Σ Retained
$12.50B
Δ Market Cap
+$2.52B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
V
$5.50
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$44.47B
Δ Market Cap
+$244.54B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
REGN
61.2% Margin of Safety
Price is 61.2% below estimated fair value
Current Price: $609.94
Fair Value: $1572.11
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
V
7.6% Overvalued
Price is 7.6% above estimated fair value
Current Price: $327.24
Fair Value: $304.21
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
REGN

What growth rate is the market pricing in at $610?

+1.6%
Market-Implied Owner Earnings Growth
Standard FCF implies +6.0%

The market implies +1.6% Owner Earnings growth, roughly in line with history — reasonably priced.

Standard FCF implies +6.0%, reflecting ongoing growth investment.

V

What growth rate is the market pricing in at $327?

+13.9%
Market-Implied Owner Earnings Growth
Standard FCF implies +13.4%

The market implies +13.9% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +13.4%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
REGN
80/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
V
99/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. ROIC Consistency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
REGN
-2.51
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
V
-2.50
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
REGN
Insiders 2.0%Institutions 92.3%Retail & Other 5.6%
No. of Institutional Holders1,990
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
V
Insiders 0.1%Institutions 91.7%Retail & Other 8.2%
No. of Institutional Holders5,856
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
REGN
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
V
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
REGN
2
Sells (3M)
10
Sells (12M)
Total value (12M): $9.47M
RYAN ARTHUR F
Director
$70,524
@ $705.24 · 2026-05-01
RYAN ARTHUR F
Director
$77,727
@ $777.27 · 2026-04-01
RYAN ARTHUR F
Director
$78,550
@ $785.50 · 2026-03-02
ZOGHBI HUDA Y
Director
$1.28M
@ $781.33 · 2026-02-19
RYAN ARTHUR F
Director
$77,853
@ $778.53 · 2026-02-09
PITOFSKY JASON
Officer
$1.59M
@ $778.52 · 2026-02-09
BASSLER BONNIE L
Director
$1.20M
@ $800.00 · 2026-01-07
BASSLER BONNIE L
Director
$570,000
@ $750.00 · 2025-11-20
PITOFSKY JASON
Officer
$280,766
@ $651.43 · 2025-11-07
POON CHRISTINE A
Director
$4.25M
@ $654.27 · 2025-10-29
MCCOURT MARION E
Officer
$844,610
@ $844.61 · 2024-11-01
RYAN ARTHUR F
Director
$104,878
@ $1048.78 · 2024-10-01
MCCOURT MARION E
Officer
$1.05M
@ $1054.06 · 2024-10-01
RYAN ARTHUR F
Director
$117,868
@ $1178.68 · 2024-09-03
MCCOURT MARION E
Officer
$1.18M
@ $1178.73 · 2024-09-03
POON CHRISTINE A
Director
$12.55M
@ $1158.17 · 2024-08-15
BASSLER BONNIE L
Director
$884,520
@ $1170.00 · 2024-08-15
MURPHY ANDREW J
Officer
$7.34M
@ $1153.15 · 2024-08-14
STAHL NEIL E
Officer
$5.64M
@ $1084.54 · 2024-08-08
PITOFSKY JASON
Officer
$521,090
@ $1070.00 · 2024-08-07
BASSLER BONNIE L
Director
$842,940
@ $1115.00 · 2024-08-02
RYAN ARTHUR F
Director
$107,467
@ $1085.53 · 2024-08-01
RYAN ARTHUR F
Director
$1,100
@ $1100.00 · 2024-08-01
MCCOURT MARION E
Officer
$1.21M
@ $1060.86 · 2024-08-01
LAROSA JOSEPH J
General Counsel
$2.03M
@ $1088.95 · 2024-07-11
RYAN ARTHUR F
Director
$105,924
@ $1059.24 · 2024-07-01
MCCOURT MARION E
Officer
$1.19M
@ $1047.11 · 2024-07-01
BASSLER BONNIE L
Director
$802,872
@ $1062.00 · 2024-06-24
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
V
2
Sells (3M)
17
Sells (12M)
Total value (12M): $53.88M
SUH CHRIS
Chief Financial Officer
$3.46M
@ $324.81 · 2026-05-12
MCINERNEY RYAN
Chief Executive Officer
$10.70M
@ $340.14 · 2026-04-29
CARNEY LLOYD A
Director
$201,253
@ $309.62 · 2026-03-11
MCINERNEY RYAN
Chief Executive Officer
$3.66M
@ $349.18 · 2026-01-02
ROTTENBERG JULIE B
General Counsel
$699,315
@ $345.00 · 2025-12-11
MCINERNEY RYAN
Chief Executive Officer
$3.57M
@ $340.07 · 2025-12-11
TANEJA RAJAT
Officer
$7.84M
@ $330.14 · 2025-12-02
FABARA PAUL D
Officer
$2.50M
@ $331.45 · 2025-12-02
TANEJA RAJAT
Officer
$2.08M
@ $330.00 · 2025-11-21
FABARA PAUL D
Officer
$707,917
@ $325.93 · 2025-11-21
CARNEY LLOYD A
Director
$302,832
@ $336.48 · 2025-11-04
MCINERNEY RYAN
Chief Executive Officer
$3.58M
@ $341.00 · 2025-11-03
MCINERNEY RYAN
Chief Executive Officer
$3.59M
@ $342.30 · 2025-10-01
MCINERNEY RYAN
Chief Executive Officer
$3.65M
@ $348.57 · 2025-09-02
ROTTENBERG JULIE B
General Counsel
$697,329
@ $344.02 · 2025-08-18
MCINERNEY RYAN
Chief Executive Officer
$3.60M
@ $343.13 · 2025-08-14
MCINERNEY RYAN
Chief Executive Officer
$3.05M
@ $353.82 · 2025-07-01
FABARA PAUL D
Officer
$4.36M
@ $375.00 · 2025-06-11
TANEJA RAJAT
President
$18.44M
@ $368.87 · 2025-06-05
FABARA PAUL D
Officer
$17.10M
@ $370.00 · 2025-06-05
MCINERNEY RYAN
Chief Executive Officer
$3.13M
@ $362.77 · 2025-06-02
FABARA PAUL D
Officer
$6.32M
@ $357.45 · 2025-05-12
FABARA PAUL D
Officer
$5.26M
@ $355.04 · 2025-05-08
ROTTENBERG JULIE B
General Counsel
$889,868
@ $345.58 · 2025-05-01
MCINERNEY RYAN
Chief Executive Officer
$2.98M
@ $345.58 · 2025-05-01
MCINERNEY RYAN
Chief Executive Officer
$3.02M
@ $350.44 · 2025-04-01
FABARA PAUL D
Officer
$13.40M
@ $340.41 · 2025-03-19
FABARA PAUL D
Officer
$12.88M
@ $327.20 · 2025-03-14
MCINERNEY RYAN
Chief Executive Officer
$3.13M
@ $363.00 · 2025-03-03
ANDRESKI PETER M
Officer
$815,314
@ $349.62 · 2025-02-07
MAHON TULLIER KELLY
Officer
$11.80M
@ $349.77 · 2025-02-07
ROTTENBERG JULIE B
General Counsel
$874,480
@ $340.00 · 2025-02-03
MCINERNEY RYAN
Chief Executive Officer
$2.93M
@ $340.00 · 2025-02-03
MCINERNEY RYAN
Chief Executive Officer
$2.74M
@ $317.78 · 2025-01-02
TANEJA RAJAT
Officer
$11.15M
@ $315.55 · 2024-12-13
MCINERNEY RYAN
Chief Executive Officer
$2.73M
@ $316.90 · 2024-12-02
FABARA PAUL D
Officer
$668,603
@ $307.97 · 2024-11-22
ROTTENBERG JULIE B
General Counsel
$741,996
@ $288.49 · 2024-11-01
MCINERNEY RYAN
Chief Executive Officer
$2.49M
@ $288.49 · 2024-11-01
MCINERNEY RYAN
Chief Executive Officer
$2.39M
@ $276.97 · 2024-10-01
MCINERNEY RYAN
Chief Executive Officer
$2.38M
@ $276.37 · 2024-09-03
ROTTENBERG JULIE B
General Counsel
$707,300
@ $275.00 · 2024-08-29
MCINERNEY RYAN
Chief Executive Officer
$2.37M
@ $275.00 · 2024-08-29
MAHON TULLIER KELLY
Officer
$10.12M
@ $267.64 · 2024-08-16
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
REGN
FearGreed
😐Neutral(43/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
V
FearGreed
😐Neutral(57/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
REGN
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (43)
V
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (57)
View REGN Full AnalysisView V Full Analysis

Frequently Asked Questions: REGN vs V

Is Regeneron Pharmaceuticals, Inc. or Visa Inc. more undervalued in 2026?▼

Based on our discounted cash flow model, REGN trades at a 61.2% margin of safety (intrinsic value $1572 vs. price $610), compared to V's -7.6% margin of safety (intrinsic $304 vs. $327).

Which stock has a wider economic moat, Regeneron Pharmaceuticals, Inc. or Visa Inc.?▼

V scores 99/100 (Wide moat), while REGN scores 80/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Which company has better free cash flow, Regeneron Pharmaceuticals, Inc. or Visa Inc.?▼

Regeneron Pharmaceuticals, Inc. (REGN) generates a 5.1% free cash flow yield, compared to Visa Inc.'s 3.3%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, Regeneron Pharmaceuticals, Inc. or Visa Inc.?▼

V earns 38.4% ROIC versus REGN's 7.1%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, Regeneron Pharmaceuticals, Inc.'s or Visa Inc.'s?▼

V's dividend earns a safety score of 94/100 (Very Safe), compared to REGN's 85/100 (Very Safe). V has raised its dividend for 3 consecutive years.